Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$671.64 ▲ +120.43
(+21.85%)
MKT CAP: $43.42B • VOL: 1.98M
52W L $501 52W H $770
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$564
MEDIAN
$752
MEAN
$766
HIGH
$913
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE IDXX TAPE
IDXX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $812.68 | $772.39 | 2025-02-14 | $611.19 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $846.27 | $792.54 | 2025-02-06 | $631.34 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $765.67 | $738.80 | 2025-01-29 | $644.77 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $685.07 | — | 2025-01-17 | $658.21 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $591.04 | $638.06 | 2025-01-09 | $597.76 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $799.25 | $698.51 | 2024-12-18 | $584.33 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $651.49 | $678.36 | 2024-12-04 | $624.63 | -4.3% | 48% | C |